OBJECTIVE: The aim was to examine the immune reconstitution after current chemotherapy for childhood ALL, with a special focus on finding immunologic variables that predict a poor immune response to vaccinations. PROCEDURE: In a cross-sectional study of 31 children after treatment with the NOPHO ALL-1992 protocol peripheral blood lymphocyte subsets, T- and B-cell function in vitro and serum immunoglobulins (Ig) were measured. All patients were examined once, at 1 or at 6 months after cessation of chemotherapy, immediately before vaccination with DT and Hib. RESULTS: Lymphocytes, T-cells, and CD4+ T-cells were low at 6 months after treatment. Naive T-cell subsets were more reduced than memory subsets. In the high risk (HR) ALL group, CD8+ T-cells were reduced at 6 months. NK-cells were low at 1 month, but normal at 6 months; however, the CD3+CD56+ (NKT) subset was reduced at both time points. Total B-cell number was low at 1 month, but normal at 6 months. A relative increase of CD5+ B-cells (B-1 cells) was evident, particularly in the HR group. Antigen-independent T- and B-cell function in vitro were affected at 1 month, but virtually normalized at 6 months. Serum IgM level was decreased at 1 month and IgG3 level was increased at 1 and 6 months. CONCLUSIONS: This study shows that immune reconstitution after childhood ALL is slower than previously reported and emphasizes the influence of treatment intensity. The most intensively treated patients still have persistent abnormalities in T-, B-, and NK-cell subsets at 6 months post therapy and show a poor response to immunization with T-cell dependent antigens. In the HR group, routine re-immunizations before this time point are of limited benefit, and the effect of repeated vaccinations should be evaluated. 2004 Wiley-Liss, Inc.
OBJECTIVE: The aim was to examine the immune reconstitution after current chemotherapy for childhood ALL, with a special focus on finding immunologic variables that predict a poor immune response to vaccinations. PROCEDURE: In a cross-sectional study of 31 children after treatment with the NOPHO ALL-1992 protocol peripheral blood lymphocyte subsets, T- and B-cell function in vitro and serum immunoglobulins (Ig) were measured. All patients were examined once, at 1 or at 6 months after cessation of chemotherapy, immediately before vaccination with DT and Hib. RESULTS: Lymphocytes, T-cells, and CD4+ T-cells were low at 6 months after treatment. Naive T-cell subsets were more reduced than memory subsets. In the high risk (HR) ALL group, CD8+ T-cells were reduced at 6 months. NK-cells were low at 1 month, but normal at 6 months; however, the CD3+CD56+ (NKT) subset was reduced at both time points. Total B-cell number was low at 1 month, but normal at 6 months. A relative increase of CD5+ B-cells (B-1 cells) was evident, particularly in the HR group. Antigen-independent T- and B-cell function in vitro were affected at 1 month, but virtually normalized at 6 months. Serum IgM level was decreased at 1 month and IgG3 level was increased at 1 and 6 months. CONCLUSIONS: This study shows that immune reconstitution after childhood ALL is slower than previously reported and emphasizes the influence of treatment intensity. The most intensively treated patients still have persistent abnormalities in T-, B-, and NK-cell subsets at 6 months post therapy and show a poor response to immunization with T-cell dependent antigens. In the HR group, routine re-immunizations before this time point are of limited benefit, and the effect of repeated vaccinations should be evaluated. 2004 Wiley-Liss, Inc.
Authors: S Masouridi-Levrat; A Pradier; F Simonetta; L Kaiser; Y Chalandon; E Roosnek Journal: Bone Marrow Transplant Date: 2015-11-09 Impact factor: 5.483
Authors: Joanna L Perkins; Yan Chen; Anne Harris; Lisa Diller; Marilyn Stovall; Gregory T Armstrong; Yutaka Yasui; Leslie L Robison; Charles A Sklar Journal: Cancer Date: 2014-05-13 Impact factor: 6.860
Authors: Gregory M T Guilcher; Linda Rivard; Jennifer T Huang; Nicola A M Wright; Lynette Anderson; Hesham Eissa; Wendy Pelletier; Shanti Ramachandran; Tal Schechter; Ami J Shah; Ken Wong; Eric J Chow Journal: Lancet Child Adolesc Health Date: 2021-02-16
Authors: L Wang; H Hu; R Zhang; X Zheng; J Li; J Lu; Y Zhang; P Qi; W Lin; Y Wu; J Yu; J Fan; Y Peng; H Zheng Journal: Clin Exp Immunol Date: 2020-10-05 Impact factor: 4.330
Authors: María Victoria Martínez-Sánchez; José Luis Fuster; José Antonio Campillo; Ana María Galera; Mar Bermúdez-Cortés; María Esther Llinares; Eduardo Ramos-Elbal; Juan Francisco Pascual-Gázquez; Ana María Fita; Helios Martínez-Banaclocha; José Antonio Galián; Lourdes Gimeno; Manuel Muro; Alfredo Minguela Journal: Cancers (Basel) Date: 2021-05-11 Impact factor: 6.639